Article

Patient Forum in NYC will Focus on Hairy Cell Leukemia

Author(s):

Hairy Cell Leukemia Foundation

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia.

The Hairy Cell Leukemia Foundation will host a free patient forum on July 17th with guest speaker Dr. Martin Tallman from Memorial Sloan Kettering Cancer Center. This forum is free and open to the public and will cover a range of issues related to patients’ journey with hairy cell leukemia. There will be ample time for audience Q&A.

Understanding Hairy Cell Leukemia

When: July 17th at 5:30 pm Eastern

Where: Webster Library, 1465 York Avenue, New York City, NY

Featuring: Dr. Martin Tallman, Memorial Sloan Kettering Cancer Center

Hosted by the Hairy Cell Leukemia Foundation

Advance registration is encouraged: https://www.hairycellleukemia.org/forums

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
Image of FDA sign.
April 8th 2025

FDA Grants Positive Review for AML Drug Trial, First Dosing in 2025

Spencer Feldman
The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory leukemia or lymphoma: © nobeatsoffierce - stock.adobe.com
March 22nd 2025

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

Alex Biese
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Nutrition is a challenge for many patients with cancer. © - stock.adobe.com
March 12th 2025

Nutrition is Key Following a Cancer Diagnosis

The Leukemia & Lymphoma Society
Nutrition is a challenge for many patients with cancer.
Cancer is one of the most expensive medical conditions to treat in the U.S. - © stock.adobe.com
March 12th 2025

The Leukemia & Lymphoma Society is Helping Patients With Medial Debt

The Leukemia & Lymphoma Society
Cancer is one of the most expensive medical conditions to treat in the U.S.